News and Announcements
Cirrus Materials Science announces Offer Terms for Pre-Series A Investment Round
- Published July 31, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
It is with great pleasure that the board of Cirrus Materials Science announces the Offer Period and Key Terms for investors participating in our Pre-Series A Investment Round. The purpose of the pre-Series A investment is to fund customer acquisition including major near-term sales prospects, intellectual property protection, and expansion capital. The Offer Period for the current capital round will open to both qualified investors and existing shareholders on August 1st and close to all parties on August 30th unless extended by the board.
The key terms are:
| Capital Raise Amount: | NZD1,300,000 for 325,000 shares |
| Minimum: | NZD300,000. |
| Pre-money Valuation: | NZD8,307,432. |
| Issue price: | NZD4.00 per share. |
| Class: | Ordinary Shares. |
| Minimum Subscription Amount: | 5,000 Shares. |
| Oversubscriptions: | Up to NZD300,000 or 75,000 shares is permitted. |
| Scaling basis (if required): | After pre-emptives, first come first served. |
| Opens: | 1 August 2019. |
| Closing date: | 30 August 2019 (unless extended). |
| Payment: | Due no later than five business days after the Offer closes. |
| Applications: | This Offer is made in reliance on the exclusions in Schedule 1 of the New Zealand Financial Markets Conduct Act 2013 (FMCA). |
| Contact: | Register your interest here for offer documents, terms, and access to due diligence materials. |
For more information on Cirrus Materials Science, register your interest here.
About Cirrus Materials Science
Cirrus is a New Zealand-based materials design business serving major manufacturing customers in Australasia, US, EU and Asia.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
